On January 30, Forbes China revealed its list of emerging unicorns in China for 2022. Forbes China tracked more than 2,000 startups that raised more than RMB 200 million or USD 30 million in a single round of funding in the past year and are likely to cross over into the unicorn category. Using desktop research and questionnaires, the Forbes China research team identified 74 emerging unicorns in China.
Three companies involved in in vitro diagnostics-related businesses, Singlera, Magarobo and Zencore made the list.
Since its establishment in 2014, Singlera has been aiming at tackling early cancer screening and diagnosis, and the company has developed a series of detection solutions for tumors and genetic diseases based on molecular diagnostic technologies. As a leader and promoter of methylation detection technology, Singlera Bio provides a full cycle of products and services for risk assessment, early screening and diagnosis, medication guidance and recurrence monitoring of high-incidence cancers. The company has a rich product pipeline covering pan-cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, thyroid cancer and other high-incidence cancer types.
Since the establishment in 2016, MEGAROBO has been devoting in becoming an intelligent automation expert in life sciences, clinical diagnostics, applied chemistry, advanced manufacturing and more fields, enabling breakthrough innovation of industry and productivity to create a more efficient, healthier and better world. MEGAROBO is focusing on robotics and AI technology R&D applied in industrial scenarios, where we provide intelligent automation products and total solutions to our partners. With MEGALAB, an automated intelligent life sciences lab developed by MEGAROBO, we enable automation transformation in drug discovery and development, cell and gene therapy, organoid development, and synthetic biology.
Additionally, MEGAROBO is a leading innovator in the semiconductor manufacturing and testing equipment industry, providing numerous mature products and solutions to top industry players. MEGAROBO has assembled a talent and interdisciplinary team including close to 100 scientists with PhD degrees and 500 experienced engineers and has filed over 350 patents. MEGAROBO is headquartered in Suzhou, China, with local branches in Beijing, Shanghai, and Shenzhen. And overseas headquarters is located in Singapore, with R&D centers in the United States, the United Kingdom and Japan.
MEGAROBO has closed the Series C financing. We have been favoured and recognized by many top strategic and institutional investors, such as WuXi AppTec, Bosch, Goldman Sachs Asset Management, Asia Investment Capital, GGV Capital, Sinovation Ventures, Joy Capital, and Matrix Partners China, Pavilion Capital.
Zencore Biologics is a CDMO provider headquartered in Shanghai, China. Zencore has an R&D facility located in Maryland, United States. Zencore provides one-stop-shop services for biologics from pre-clinical research to commercial manufacturing and customized cell culture medium services for mammalian cell-based protein production. Zencore supports the R&D and production of protein drugs for its domestic and global clients. The services and solutions provided include:
• Biologics CDMO
• Antibody drug conjugate (ADC) CDMO
• Cell culture medium support: the development & manufacturing
• Analytical development and characterization services
• QC testing & regulatory filings
With two CDMO facilities of 600,000 sq ft in total, Zencore provides a pilot scale production with 4¡Á200L and 1¡Á500L single use bioreactors, and the state-of-the-art commercial GMP manufacturing services with 3¡Á2,000L single use and 3¡Á5,000L stainless steel bioreactors in separate production suites, followed by corresponding purification, formulation, and fill and finish lines.
Both Singlera & Megarobo will participate in 2023 CACLP and CISCE.
